Sponsor:
Abbott Diabetes Care
Code:
NCT06668935
Conditions
Diabetes Mellitus
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists
Brief summary:
Conditions
Diabetes Mellitus
Study ID
NCT06668935
Start date
Oct 24, 2024
Status verified date
Oct, 2024
Completion date
Jan, 2027
Anticipated
Primary completion date
Oct, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
800 participants
Anticipated
Arms
Randomization to FSL 3 or Standard of Care
Interventions
To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists
Primary outcome measure
Central contacts
Locations
East Coast Institute for Research, LLC
Recruiting
Jacksonville, Florida, United States, 32216
Contacts
Principal Investigator:
Wasim Deeb, MD
Excellence Medical and Research
Recruiting
Miami Gardens, Florida, United States, 33169
Contacts
Principal Investigator:
Miguel Trujillo, DNP
Sponsor
Abbott Diabetes Care
Last update posted
Jan 15, 2025
Last verified
Oct, 2024
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Abbott Diabetes Care on 2025-01-15.